- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Oral zinc supplements improve survival rate in COVID patients
A recent study by Saoussen Ben Abdallah and team showed that oral zinc can reduce the 30-day mortality rate, intensive care unit (ICU) admission rate, and symptom duration in COVID-19 patients. The findings of this study were published in Clinical Infectious Diseases.
Since the coronavirus disease 2019 (COVID-19) pandemic first appeared in China in late December 2019, it has caused a global health disaster. A number of medications that were first deemed successful against COVID-19's etiological agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were later rejected. Coronavirus illness has been treated with zinc supplementation in the past (COVID-19). Therefore, the purpose of this study was to evaluate the effectiveness of zinc in treating adult COVID-19 infection patients.
Patients who tested positive for COVID-19 but did not have end-organ failure were randomized to either oral zinc for 15 days (n = 231) or a placebo (n = 239). Death due to COVID-19 or intensive care unit admission within 30 days after randomization was the main composite outcome. The duration of COVID-19 symptoms with COVID-19-related hospitalization for outpatients and the length of hospital stay for inpatients were considered secondary outcomes.
The key findings of this study were:
1. 280 patients (59.6%) were hospitalized, whereas 280 patients (40.4%) were ambulatory.
2. The zinc group's 30-day mortality rate was 6.5%, whereas the placebo group was 9.2%. ICU admission rates were, in turn, 5.2% and 11.3%.
3. In comparison to the placebo group, the zinc group's overall result was worse.
4. Patients under 65, those with concomitant conditions, and those who required oxygen treatment at baseline all showed consistent outcomes.
5. In the inpatient group, the zinc group's hospital stay was shorter than that of the placebo group; in the outpatient group, the duration of COVID-19 symptoms was shorter with zinc medication than it was with placebo.
6. Throughout the research, no significant adverse effects were noticed.
In conclusion, In patients with COVID-19, 15 days of oral zinc therapy is related with a roughly 40% decrease in mortality and ICU hospitalization, as well as a shortening of symptom duration. In the absence of a targeted, efficient curative therapy, these data have significant therapeutic implications.
Reference:
Ben Abdallah, S., Mhalla, Y., Trabelsi, I., Sekma, A., Youssef, R., Bel Haj Ali, K., Ben Soltane, H., Yacoubi, H., Msolli, M. A., Stambouli, N., Beltaief, K., Grissa, M. H., Hezbri, K., Belguith, A., … Nouira, S. (2022). Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial. In Clinical Infectious Diseases. Oxford University Press (OUP). https://doi.org/10.1093/cid/ciac807
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751